Considering that ACE2 is overexpressed in patients on RAAS inhibitor therapy, the hypothesis that RAAS inhibitor drugs may alter the risk of developing more severe forms of COVID‐19 by facilitating viral entry and replication in human cells and altering the basal balance of RAAS is a matter of debate (Baral et al., 2020; Kaur et al., 2020; Zheng et al., 2020). Here, ACE2 is linked to COVID-19.